Personalised Oncology Platform PreComb Therapeutics Closes 1.3 Million CHF Pre-Series A Round

Cancer remains one of the leading killers, with about 10 million deaths worldwide attributed to the disease in 2020. While personalised medicine is gaining traction in other medical fields, only 5%–10% of cancer patients currently benefit from customised treatment plans matching their unique genetic profile. 

PreComb’s groundbreaking technology generates 3D tumour twins that mimic the behaviour and characteristics of the original tumour. The 3DTwins® then undergo AI-supported testing using a broad range of cancer drugs to determine which treatments will be most effective for an individual cancer patient. In the future, physicians will be able to use PreComb to conduct fully automated tests directly in their clinics for rapid results and direct treatment planning.

“Cancer is an incredibly individualised disease,” said Jens M. Kelm, CEO and co-founder of PreComb. “Success of treatment depends largely on the unique tumour profile as well as the patient's biology. PreComb removes the guesswork from treatment protocols to ensure patients receive therapies tailored to their unique needs. We look forward to working with our new investors to advance our technology’s capabilities and reach.”

LongeVC Managing Partner and co-founder Sergey Jakimov said, “Personalised medicine is the future of healthcare. PreComb is using this technology to transform the narrative on cancer treatment and help individuals live longer and healthier lives post-diagnosis. We are proud to back their industry-defining work in oncology.”

Chairman of Kinled Patrick Aisher said, “PreComb will not only help patients receive the best treatments available but also serve as an invaluable resource for physicians and drug developers. By investing in their technology, we aim to unlock a greater understanding of cancer medicine for all.”